The authors concluded that extended thromboprophylaxis with low molecular weight heparin should be considered a safe and useful method for the prevention of venous thromboembolism in high-risk major abdominal surgery. This was generally a well-conducted review and the authors' conclusions were likely to be reliable.
To compare the safety and efficacy of extended thromboprophylaxis (ETP) with conventional in-hospital prophylaxis in patients undergoing major abdominal surgery.
Searching
MEDLINE, EMBASE, LILACS, the Cochrane Library, Cochrane Controlled Trials Register and the registry of the United States National Institutes of Health were searched from inception to February 2007. Search terms were reported. No language restrictions were applied. In addition, abstracts of four specified relevant meetings (2000 ( to February 2007 and references of identified studies, reviews and guidelines were screened. Manufacturers of antithrombotic agents were contacted and national and international experts consulted for additional studies.
Study selection
Randomised controlled trials (RCTs) and controlled clinical trials that compared an ETP regimen (for at least 21 days after surgery) with the same regimen limited to the in-hospital period in adults (aged >18 years) undergoing major abdomino-pelvic surgery were eligible for inclusion. Details of eligible ETP regimens were specified in the review. Studies had to objectively assess venous thromboembolism (VTE) at the end of the observation period, assess thromboembolic events using any of the specified methods and adequately report bleeding events and mortality. In addition, studies had to be double-blinded or open with blinded outcome assessment and score more than 2 on the Jadad scale.
The included studies evaluated low molecular weight heparin (LMWH, tinzaparin, dalteparin and enoxaparin) with or without elastic stockings; the duration of ETP regimens ranged from 25 to 31 days. All studies randomised patients postoperatively. Most patients (71 per cent) underwent surgery for cancer. The median age was 67 years (range 22 to 93 years). All studies evaluated VTE using lower limb bilateral venography (after a mean of 32 days post surgery). The review also included some patients who had undergone non-cardiac thoracic surgery, since they could not be separated from the group of interest. The duration of follow-up was 28 days or three months.
Two reviewers independently selected studies. Discrepancies were resolved through discussion with the aid of a third reviewer if required.
Assessment of study quality
Two reviewers independently assessed validity using the Jadad scale (reporting of randomisation, blinding and withdrawals). The maximum possible score was 5. Discrepancies were resolved through discussion with the aid of a third reviewer if required.
